Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 16/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 15/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | GRM5 | P41594 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19216402 | 0.90 | GRIN2B (0.81) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL3392267 | 0.90 | GRIN2B (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL7884889 | 0.88 | GRIN2B (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL19213976 | 0.88 | GRIN2B (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL3393378 | 0.88 | GRIN2B (0.98) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL3396633 | 0.87 | GRIN1 (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL3394898 | 0.86 | GRIN1 (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL3424183 | 0.86 | GRIN2B (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL18587450 | 0.86 | GRIN1 (0.81) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL19213968 | 0.83 | GRIN2B (0.78) | GRIN2BGRIN1SIGMAR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | WESTFALISCHE WILHELMS-UNIVERSITAT MUNSTER (DE) | 2018-09-06 | — | — | US | disclosed |
| EP-3344257-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20170224852-A1 | BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | WESTFAELISCHE WILHELMS-UNIVERSITAET (DE) | 2017-08-10 | — | — | US | disclosed |
| WO-2017036880-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2017-03-09 | — | — | WO | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
| EP-2246331-A1 | NR2B-selective NMDA-receptor antagonists | Westfälische Wilhelms-Universität Münster (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010122134-A1 | NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS | Westfälische Wilhelms Universität Münster (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122134-A1 | NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS | Westfälische Wilhelms Universität Münster (DE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250308-A1 | NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES | GRIN1, GRIN2B, GRIN3B | GRIN2B 2/4885GRIN1 1/4885SIGMAR1 477/4885 |
| US-20170224852-A1 | BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | OPRK1, GRIN1, OPRL1 | GRIN2B 9/4885GRIN1 2/4885SIGMAR1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.